Bruker BioSpin AG rents a property in Faellanden, Switzerland from ZeroC Project GmbH under a lease agreement
| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Frank H. Laukien
Also a director
Chairman, President and Chief Executive Officer
|
66 | Not stated | Not stated | $4,706,388 | |
|
Gerald N. Herman
Executive Vice President and Chief Financial Officer
|
68 | Not stated | 2016 | $2,010,308 | |
|
Burkhard A. Prause
PRES. & CEO, BRUKER BEST
Title from the Form 4 dated Aug 15, 2026
|
59 | Not stated | Not stated | Not reported | |
|
Thomas Bures
Chief Accounting Officer
Title from the Form 4 dated Aug 15, 2026
|
Not stated | Not stated | Not stated | Not reported | |
|
Falko Busse
President, Bruker BioSpin Group
|
59 |
Since 2018
8 years
|
2015 | Not reported | |
|
Mark R. Munch
President of Bruker NANO Group and Corporate Executive Vice President
|
64 | Not stated | Not stated | Not reported | |
|
Juergen W. Srega
President, Bruker CALID Group and Bruker Daltonics Division
|
71 | Not stated | Not stated | Not reported | |
|
Wolfgang Pusch
President BMID Group
Title from the Form 4 dated Aug 15, 2026
|
Not stated | Not stated | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Bruker BioSpin AG rents a property in Faellanden, Switzerland from ZeroC Project GmbH under a lease agreement
Equipment sales to and purchases from Promega Corporation in the ordinary course of business
Purchased 687,500 shares of Gauss Fusion GmbH from Bruker EAS GmbH, a wholly owned subsidiary of the Company
Convertible loan agreement to Gauss Fusion GmbH
Collectively contributed additional funds to Gauss Fusion GmbH alongside Dr. Laukien's convertible loan
Equipment sales in the ordinary course of business to Asahi Kasei Corporation
Employment with Bruker Daltonik GmbH as VP & Managing Director of Bruker Biosensors, with total compensation
Employment with Bruker Switzerland AG as Director of Group Strategy Development, with total compensation
Expected total compensation upon separation from the Company effective June 30, 2026
Loading...